Dr. Busti explains why the PARADIGM-HF trial changed treatment for heart failure with reduced ejection fraction (HFrEF), connecting sacubitril/valsartan to the clinical evidence behind angiotensin receptor-neprilysin inhibitor (ARNI) therapy.

Why replace an ACE inhibitor in a patient who seems stable? Follow the rationale for neprilysin inhibition, the role of natriuretic peptides, and the reason sacubitril is paired with valsartan. Then examine the comparison with enalapril: cardiovascular death or first heart-failure hospitalization, relative versus absolute benefit, symptomatic hypotension, and the run-in period that shaped trial eligibility.

This Landmark Clinical Trials episode also puts PIONEER-HF, PROVE-HF, PARAGON-HF, and PARADISE-MI into perspective without treating biomarker changes or remodeling associations as proof of a survival mechanism. The discussion connects AHA/ACC/HFSA guidance to practical heart failure treatment, including ARNI within the four foundational drug classes, switching precautions, dosing and monitoring, and interpretation of BNP versus NT-proBNP.

Designed for healthcare learners and practicing clinicians across medicine, nursing, and pharmacy, this lecture explains what the trial established, why the treatment strategy made sense, and where its findings should not be generalized.

When we understand the why, we improve the how.

Get more with a free membership at https://www.thisiswhy.health/

Access free downloads from our videos
Access deep-dive content from Dr. Busti
Organize content via playlists & collections
Join live Q&A
Receive member newsletters
Coupons & discounts for exam prep resources

Chapter Table of Contents
0:00 - Introduction
1:33 - Why the Trial Was Needed
3:09 - How Sacubitril/Valsartan Works
7:56 - PARADIGM-HF Trial Design
10:56 - Key Results and Clinical Outcomes
14:38 - Why the Trial Changed Practice & Its Limitations
17:18 - Later Evidence and Where ARNI Fits Today
20:18 - Practical Use, Dosing, Safety, and Takeaways

If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this channel continue producing free, high-yield medical education content.

Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!

#PARADIGMHF #SacubitrilValsartan #HFrEF #ARNI #DrBusti

Speaker:
Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education.
Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes.

About This Channel:
This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines aligned with the principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC).

Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.